Genentech's Giredestrant Plus Everolimus Cuts Risk Of Progression Or Death 44% In ITT And 62% In ESR1-Mutated ER-Positive Advanced Breast Cancer In Phase III EvERA; FDA Goal Dates Are Dec. 18 For Advanced Disease And Nov. 30 For Early-Stage Disease
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard endocrine therapy plus everolimusBy targeting resistance to
Genentech's new breast cancer drug combo worked really well in testing. This is a sign the company might get FDA approval soon and help patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.